Evolocumab before PCI for acute MI improves LDL control

MUNICH — Early administration of evolocumab prior to PCI for acute MI significantly improved patients’ chances of meeting guideline-recommended LDL goals by 1 year, but did not impact clinical outcomes vs. standard care.Fewer patients who received standard care alone achieved LDL control at 1 year compared with those who initiated evolocumab (Repatha, Amgen) prior to PCI on top of